Bruce N. Jacobs is CFO at Kymera Therapeutics, Inc. (KYMR). They have made 10 open-market trades across 1 company since 2021, most recently 2026-06-30.
CIK 0001821074
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 10 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| KYMR | 244,883 | $25.6M |
Shares reported on the most recent Form 4, priced at the 2026-07-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KYMR | SELL · 10b5-1 | 2026-06-30 | 2026-07-02 | $114.96 | $8.9M | +1.8% | -10.6% | -0.0% |
| KYMR | SELL | 2026-03-02 | 2026-03-04 | $87.50 | $1.1M | -6.9% | -0.3% | -16.5% |
| KYMR | SELL · 10b5-1 | 2025-09-17 | 2025-09-17 | $50.00 | $4.0M | +18.4% | +21.1% | +70.5% |
| KYMR | SELL | 2025-03-03 | 2025-03-03 | $30.40 | $389K | +15.1% | -9.3% | +48.4% |
| KYMR | SELL | 2024-03-04 | 2024-03-04 | $41.81 | $318K | -5.6% | -11.3% | -24.6% |
| KYMR | SELL · 10b5-1 | 2023-03-02 | 2023-03-03 | $31.00 | $42K | -5.5% | -9.8% | -10.7% |
| KYMR | SELL | 2022-01-12 | 2022-01-14 | $51.84 | $1.6M | -8.2% | -0.7% | -5.9% |
| KYMR | SELL | 2021-12-03 | 2021-12-03 | $53.54 | $1.1M | +5.1% | +22.5% | -28.5% |
| KYMR | SELL | 2021-09-03 | 2021-09-03 | $60.12 | $601K | +7.4% | +0.6% | -10.4% |
| KYMR | SELL | 2021-06-03 | 2021-06-04 | $46.87 | $937K | +2.3% | +13.2% | +26.4% |
| KYMR | SELL | 2021-03-11 | 2021-03-15 | $60.15 | $1.2M | -34.6% | -40.0% | -16.3% |
| KYMR | SELL | 2021-03-08 | 2021-03-08 | $50.57 | $895K | -1.3% | -29.6% | -0.7% |
| KYMR | SELL | 2021-03-03 | 2021-03-05 | $44.75 | $1.7M | +16.9% | -23.7% | -4.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.